Avi B. Markowitz, MD, FACP
Director and Chief, Division of Hematology/Oncology
Avi B. Markowitz, MD, FACP
Professor of Internal Medicine
Chief, Division of Hematology/Oncology
Bill and Louise Bauer Distinguished Chair in Cancer Research
Department of Internal Medicine
University of Texas Medical Branch
4.164 John Sealy Annex
301 University Blvd.
Galveston, TX 77555-0565
Dr. Avi Markowitz was born in Poughkeepsie, New York and grew up in Virginia and New Jersey. He received his undergraduate degree from Rutgers University in New Brunswick, New Jersey in 1977. He then graduated with an MD from the University of California, San Francisco School of Medicine in 1981. He completed a Residency in Internal Medicine at the University of California, San Diego in 1984. Dr. Markowitz returned to the Cancer Research Institute at the University of California, San Francisco School of Medicine where he completed his Fellowship in Medical Oncology in 1986. After working briefly as a laboratory investigator for Cetus (a biotechnology company later acquired by Chiron), he returned to the University of California, San Francisco School of Medicine as a Clinical Instructor in the Cancer Research Institute. During that time, he began his career as a clinical investigator. In 1987 Dr. Markowitz accepted a Faculty appointment at M. D. Anderson Cancer Center as an Assistant Professor in the Department of Clinical Immunology and Biological Therapy. There, he continued his clinical investigations with a variety of novel biologic agents. He completed his stay at M.D. Anderson in the Department of Gastrointestinal Medical Oncology in 1995.
Dr. Markowitz then moved to Bryan/College Station, Texas where he established two American College of Surgeons accredited Cancer Centers at St. Joseph Regional Medical Center and College Station Medical Center. He was also Director of Research and Development at St. Joseph Regional Cancer Center. In June 2005 Dr. Markowitz was recruited to UTMB as Chief of Hematology/Oncology. Since coming to UTMB he has assumed the roles of Director of the Medical Oncology Fellowship for 5 years and remains the Associate Medical Director of Experimental Therapeutics in the UTMB Comprehensive Cancer Center where he is also Director of the Oncology Clinical Trials Office which supervises all adult clinical oncology research at UTMB. Dr. Markowitz remains interested in novel drug development with a particular interest in targeted therapy.
Recent Media / Articles
- Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol 26: 4355-4356, 2008.
- Reddy NK, Markowitz AB, Abbruzzese JL, Bhutani MS. Knowledge of indications and utilization of EUS: a survey of oncologists in the USA. J Clin Gastroenterol 42 (8): 892-896, 2008.
- Wang J, Yong FK, Freeman J, Markowitz AB, Goodwin JS. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected non small cell lung cancer. Cancer 112 (2): 382-390, 2008.
- Bhutani MS, Saftiou A, Chaya C, Gupta P, Markowitz AB, Willis M, Kessel I, Sharma G, Zwischenberger JB. Irregular echogenic foci representing coagulation necrosis: a useful but perhaps under-recognized EUS echo feature of malignant lymph node invasion. J Gastrointestin Liver Dis 18 (2): 181-184, 2009.
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.